Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125305 | PMC |
| http://dx.doi.org/10.3389/fgene.2022.901664 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial: Specific targeting of MHC antigens for T-cells and immune cells in human disease.
Front Immunol
January 2025
Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Linking Long ncRNA to the Diagnosis, Pathogenesis, and Prognosis of Esophageal Cancer.
Dig Dis Sci
January 2025
Department of Gastroenterology and Hepatology, Loyola University Medical Center, 2160 S First Ave, Maywood, IL, 60153, USA.
Esophageal cancer is a common and often deadly malignancy, with treatment success depending largely on the stage at the time of diagnosis. Recently, studies have examined the role of non-coding RNAs in esophageal cancer pathogenesis, prognosis and therapy. This perspective specifically examines interactions long non-coding RNAs have with other RNA molecules in various facets of esophageal cancer.
View Article and Find Full Text PDFThe role of long non-coding RNA in myocardial ischemia/reperfusion injury.
Int J Cardiol
January 2025
School of Medicine, Northeast Ohio Medical University, Rootstown, OH, USA. Electronic address:
Let-7b-5p sensitizes breast cancer cells to doxorubicin through Aurora Kinase B.
PLoS One
January 2025
Information School, The Wave, The University of Sheffield, Sheffield, United Kingdom.
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate the expression level of the target genes in the cell. Breast cancer is responsible for the majority of cancer-related deaths among women globally. It has been proven that deregulated miRNAs may play an essential role in the progression of breast cancer.
View Article and Find Full Text PDFSafety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers.
Nat Commun
January 2025
Replicate Bioscience Inc, San Diego, CA, USA.
Self-replicating RNA (srRNA) technology, in comparison to mRNA vaccines, has shown dose-sparing by approximately 10-fold and more durable immune responses. However, no improvements are observed in the adverse events profile. Here, we develop an srRNA vaccine platform with optimized non-coding regions and demonstrate immunogenicity and safety in preclinical and clinical development.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!